Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue (NCT06740526)
A Phase 2b, Multicenter, Open-label, Single-arm Trial to Evaluate the Impact of Sibeprenlimab on Kidney Histopathology Through Repeat Kidney Biopsies in Adolescents and Adults With Immunoglobulin A Nephropathy
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 2b open-label trial to characterize histopathological biomarkers of disease in immunoglobulin A nephropathy (IgAN) and demonstrate potential changes in response to sibeprenlimab.
Who can join: Review the eligibility criteria below.
Location: Clinical Research Site 330 — Denver, Colorado
Age range: 16 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- Clinical Research Site 330 — Denver, Colorado
- Clinical Research Site 369 — Boston, Massachusetts
- Clinical Research Site 374 — Dakota Dunes, South Dakota
- Clinical Research Site 324 — Houston, Texas
- Clinical Research Site 305 — Scarborough Village, Ontario
📞 Contact the Study Coordinator
Phone: (844) 687-8522
Email: Otsuka-ProfessionalServices@otsuka-us.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in IgA Nephropathy
- A Study of Zigakibart in Adults With IgA Nephropathy — Birmingham, Alabama
- Atrasentan in Patients With IgA Nephropathy — Birmingham, Alabama
- Atrasentan in Patients With Proteinuric Glomerular Diseases — Glendale, California
- Atacicept in Subjects With IgA Nephropathy — Brisbane, California
- A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G — Lawrenceville, Georgia
- Study of BHV-1400 in IgA Nephropathy — Farmington, Connecticut
Explore by condition: All IgA Nephropathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.